FACIT-CNI-NTX Functional Assessment of Chronic Illness Therapy – Calcineurin Inhibitor Neurotoxicity For patients receiving calcium inhibitor treatment LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACIT-CNI-NTX measure: MEASURE NAME: Functional Assessment of Chronic Illness Therapy – Calcineurin Inhibitor Neurotoxicity (FACIT-CNI-NTX) VERSION: 1 NUMBER OF ITEMS: 8 PATIENT POPULATION: Patients 18 and older receiving calcium inhibitor treatment RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: CNI-NTX scale TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. RELATED MEASURES: FACT/GOG-NTX-4 , FACT/GOG-NTX , FACT/GOG-NTX-12 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACIT-CNI-NTX can be obtained by registering for permission. Users are not permitted to translate the FACIT-CNI-NTX without permission from FACIT.org. Permission from FACIT.org to translate the FACIT-CNI-NTX may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Hurt CN, Greene GJ, Friedewald J, Waterman AD, Ladner D, Tang X, Fowler K, Kaiser K, Cella D, Peipert JD. Development of a Patient Reported Outcome Measure of Side Effects for Patients Taking Calcineurin Inhibitors: The FACIT-CNI-Ntx. Am J Kidney Dis. 2025 Jan 23:S0272-6386(25)00041-1. doi: 10.1053/j.ajkd.2024.11.012. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT/GOG-NTX-4 Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity 4 Item Version LEARN MORE FACT/GOG-NTX Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity LEARN MORE FACT/GOG-NTX-12 Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity 12 Item Version LEARN MORE

FACT-GOG-NTX Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity For patients with Neurotoxicity LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FACT/GOG-NTX provides a targeted assessment of symptoms of peripheral neuropathy, including sensory, motor, and auditory problems and cold sensitivity. This instrument has been demonstrated to be reliable and has internal consistency, content validity, and concurrent validity with sensitivity to change over time among various samples of cancer patients undergoing chemotherapy. The psychometric properties of the 13-item FACT/GOG-NTX have been established with a large sample of clinical trial participants who received an oxaliplatin-based regimen for operable colorectal cancer. The FACT/GOG-NTX subscale yields a single aggregate score, which simplifies its use as a clinical trial endpoint. Individual items can be reviewed in the clinical setting to identify clinically significant symptomatology. MEASURE NAME: Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity (FACT/GOG-NTX) VERSION: 4 NUMBER OF ITEMS: 38 PATIENT POPULATION: Cancer patients 18 and older with neurotoxicity RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Neurotoxicity Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACT/GOG-NTX-4 , FACT/GOG-NTX-12, FACT/GOG-NTX-13 , FACT-Taxane DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT/GOG-NTX can be obtained by registering for permission. Users are not permitted to translate the FACT/GOG-NTX without permission from FACIT.org. Permission from FACIT.org to translate the FACT/GOG-NTX may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Almadrones L, McGuire DB, Walczak JR, Florio CM, Tian C. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A Gynecologic Oncology Group study. Oncol Nur Forum 2004; 31:615-623. Bao T, Goloubeva O, Pelser C, Porter N, Primrose J, Hester L, Sadowska M, Lapidus R, Medeiros M, Lao L, Dorsey SG, Badros AZ. A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Integr Cancer Ther. 2014; 13(5):396-404. Beijers A, Mols F, Dercksen W, Driessen C, Vreugdenhil G. Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy. J Community Support Oncol. 2014; 12(11):401-6. Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain. 2005; 6:149-58. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, Cella D. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity (FACT/GOG-NTX) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003; 13:741-748. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: The Functional Assessment of Cancer Therapy – Taxane (FACT-Taxane). Cancer 2003; 98:822-831. Cho J, Kang D, Lee JY, Kim K, Kim SJ. Impact of dose modification on intravenous bortezomib-induced peripheral neuropathy in multiple myeloma patients. Support Care Cancer. 2014; 22(10):2669-75. Driessen CM, de Kleine-Bolt KM, Vingerhoets AJ, Mols F, Vreugdenhil G. Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer. 2012; 20(4):877-81. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Galantino ML, Callens ML, Cardena GJ, Piela NL, Mao JJ. Tai chi for well-being of breast cancer survivors with aromatase inhibitor-associated arthralgias: a feasibility study. Altern Ther Health Med. 2013; 19(6):38-44. Griffith KA, Merkies IS, Hill EE, Cornblath DR. Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst. 2010; 15(4):314-25. Griffith KA, Couture DJ, Zhu S, Pandya N, Johantgen ME, Cavaletti G, Davenport JM, Tanguay LJ, Choflet A, Milliron T, Glass E, Gambill N, Renn CL, Dorsey SG. Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations. Support Care Cancer. 2014; 22(5):1161-9. Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, Weiss M, Gilman P, Mills GM, Noga SJ, Eng C, Overman MJ, Fisch MJ. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer. 2014; 22(5):1223-31. Han X, Wang L, Shi H, Zheng G, He J, Wu W, Shi J, Wei G, Zheng W, Sun J, Huang H, Cai Z. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. BMC Cancer. 2017;17(1):40. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006; 33(1):15-49. Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2011; 125(3):767-74. Huang HQ, Brady MF, Cella D, Fleming G. Validation and reduction of FACT/GOG-NTX subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer. 2007; 17:387-93. Kamimura T, Miyamoto T, Yokota N, Aoki T, Ito Y, Akashi K. Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma. Intern Med. 2014; 53(15):1651-3. Kushner DM, Connor JP, Sanchez F, Volk M, Schink JC, Bailey HH, Harris LS, Stewart SL, Fine J, Hartenbach EM; For the Wisconsin Oncology Network. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol. 2007; 105:358-64. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O'Connell MJ, Costantino JP, Wolmark N. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007; 25:2205-11. Long HJ 3rd, Monk BJ, Huang HQ, Grendys EC Jr, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV; Gynecologic Oncology Group. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study. Gynecol Oncol. 2006; 100:537-43. McArthur JH. The reliability and validity of the subjective peripheral neuropathy screen. J Assoc Nurses AIDS Care. 1998; 9:84-94. Moore DH, Donnelly J, McGuire WP, Almadrones L, Cella D, Herzog TJ, Waggoner SE. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: A Phase II study of the Gynecologic Oncology Group. J Clin Oncol 2003; 21:4207-4213. Ogawa K, Ogawa M, Nishijima K, Tsuda M, Nishimura G. Efficacy of contact needle therapy for chemotherapy-induced peripheral neuropathy. Evid Based Complement Alternat Med. 2013; 2013:928129. Oldenburg J, Fosså SD, Dahl AA. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res. 2006; 15:791-800. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lantéri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R; EORTC Quality of Life Group. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005; 41:1135-9. Ribeiro IL, Lorca LA, Cuevas-Cid R, Dixit S, Yáñez-Benavides N, Ortega-Gonzalez F. Validation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity Questionnaire for the Latin American population. International Journal of Breast Cancer. 2022; Article ID 6533797; https://doi.org/10.1155/2022/6533797 . Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006; 24:3113-20. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009; 17(12):1483-91. Spigel DR, Patel JD, Reynolds CH, Garon EB, Hermann RC, Govindan R, Olsen M, Winfree KB, Liu J, Guba SC, Socinski MA, Bonomi P. Patient-reported outcomes from POINTBREAK: The randomized, open-label, phase III study of pemetrexed (pem) + carboplatin (cb) + bevacizumab (bev) followed by maintenance pem + bev versus paclitaxel (pac) + cb + bev followed by maintenance bev in patients with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC). J Clin Oncol. 2012; 30(34_suppl):53. [abstract] Vatandoust S, Joshi R, Pittman KB, Esterman A, Broadbridge V, Adams J, Singhal N, Yeend S, Price TJ. A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Support Care Cancer. 2014; 22(2):513-8. Viala M, Bhakar AL, de la Loge C, van de Velde H, Esseltine D, Chang M, Dhawan R, Dubois D. Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis. J Clin Epidemiol. 2007; 60:670-679. Weber B, Largillier R, Ray-Coquard I, Yazbek G, Meunier J, Alexandre J, Dauba J, Spaeth D, Delva R, Joly F, Pujade-Lauraine E, Copel L; GINECO group, France. A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial. Support Care Cancer. 2013; 21(7):1947-54. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, Esaki T, Tsuji Y, Muro K, Taira K, Denda T, Funai S, Shinozaki K, Yamashita H, Sugimoto N, Okuno T, Nishina T, Umeki M, Kurimoto T, Takayama T, Tsuji A, Yoshida M, Hosokawa A, Shibata Y, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Fujikawa K, Hirashima T, Shimura T, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Hara H, Tsushima T, Ando M, Morita S, Boku N, Hyodo I. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 2016; 27(8):1539-46. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. Zanville NR, Nudelman KN, Smith DJ, Von Ah D, McDonald BC, Champion VL, Saykin AJ. Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment. Support Care Cancer. 2016; 24(11):4779-89. Zelman DC, Gore M, Dukes E, Tai KS, Brandenburg N. Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage. 2005; 29:401-10. LICENSE THIS MEASURE Related Measures Related Measures FACT/GOG-NTX-4 Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity 4 Item Version LEARN MORE FACT/GOG-NTX-13 Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity 13 Item Version LEARN MORE FACT-Taxane Functional Assessment of Cancer Therapy – Taxane LEARN MORE

Download scoring documents for this measure. BACK FACT-EGFRI-18 Scoring Downloads Download DOC

NFKSI-19 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 19 Item Version For patients with Kidney cancer; a FACT/NCCN Symptom Index LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The NCCN/FKSI-19 (NFKSI-19) is a brief, clinically relevant symptom index for assessing symptomatic response to chemotherapy for advanced kidney cancer. Items were extracted from a multidimensional cancer quality of life measurement system, the Functional Assessment of Cancer Therapy (FACT). Surveys of disease-related symptoms were presented to expert physicians and nurses at 17 National Comprehensive Cancer Network (NCCN) member institutions. In a two-step procedure, each expert narrowed the list to no more than five of the very most important to attend to when assessing the value of drug treatment for advanced disease. Symptoms endorsed at a frequency greater than chance probability were retained. The resulting NFKSI-19 is comprised of items relating to fatigue, pain, nausea, weight loss, worry about worsening condition, and contentment with current QOL, and were consistently selected by experts as priority symptoms. MEASURE NAME: National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 19 Item Version (NFKSI-19) VERSION: 2 NUMBER OF ITEMS: 19 PATIENT POPULATION: Kidney cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Disease-Related Symptoms – Physical, Disease-Related Symptoms – Emotional, Treatment Side-Effects, Function/Well-Being TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores available. RELATED MEASURES: FKSI , FKSI-DRS , FKSI-10 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the NFKSI-19 can be obtained by registering for permission. Users are not permitted to translate the NFKSI-19 without permission from FACIT.org. Permission from FACIT.org to translate the NFKSI-19 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network ; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Rao, D., Butt, Z., Rosenbloom, S., Robinson, D., von Roenn, J., Kuzel, T., & Cella, D. A comparison of the renal cell carcinoma symptom index (RCC-SI) and the Functional Assessment of Cancer Therapy – kidney symptom index (FKSI). Journal of Pain and Symptom Management 2009; 38(2): 291-298. doi: 10.1016/j.jpainsymman.2008.08.013. Rosenbloom, S., Yount, S., Yost, K., Hampton, D., Paul, D., Abernethy, A., Jacobsen, P., Syrjala, K., Von Roenn, J., & Cella, D. Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: Measurement compliance with regulatory demands. Farquhar, I., Summers, K., Sorkin, A. (Eds.). The Value of Innovation: Impacts on Health, Life Quality and Regulatory Research. Emerald Group Publishing Inc. 2007; 16: 53-66. doi: 10.1016/S0194-3960(08)16003-6. Rothrock, N., Jensen, S., Beaumont, J., Abernethy, A., Jacobsen, P., Syrjala, K., & Cella, D. Development and Initial Validation of the NCCN/FACT Symptom Index for Kidney Cancer. Value in Health 2013; 16(5): 789-796. doi: 10.1016/j.jval.2013.04.015. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FKSI Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 15 Item Version LEARN MORE FKSI-DRS Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - Disease Related Symptoms LEARN MORE FKSI-10 Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 10 Item Version LEARN MORE

PROMIS SF v1.0-Dyspnea-Severity 5b Patient Reported Outcomes Measurement Information System - Short Form - Dyspnea-Severity 5b For patients with dyspnea LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The PROMIS SF v1.0 – Dyspnea-Severity 5b includes 5 items from part I of the FACIT-Dyspnea adopted by the PROMIS Health Organization. MEASURE NAME: Patient Reported Outcomes Measurement Information System - Short Form - Dyspnea-Severity 5b VERSION: 1 NUMBER OF ITEMS: 5 PATIENT POPULATION: Dyspnea patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 4 point Likert-type scale DATA COLLECTION: Paper and electronic For permission to implement and administer the measure electronically, please visit: https://www.healthmeasures.net/implement-healthmeasures/administration-platforms ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Severity TIME FOR COMPLETION: Less than 5 minutes SCORING: PROMIS Scoring Service: http://www.healthmeasures.net/score-and-interpret/calculate-scores/scoring-instructions RELATED MEASURES: FACIT-Dyspnea , PROMIS SF v1.0 – Dyspnea-Severity 10a , PROMIS SF v1.0 – Dyspnea-Severity 5a DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the PROMIS-SF-v1.0-Dyspnea-Severity 5b can be obtained by registering for permission. Users are not permitted to translate the PROMIS-SF-v1.0-Dyspnea-Severity 5b without permission from FACIT.org. Permission from FACIT.org to translate the PROMIS-SF-v1.0-Dyspnea-Severity 5b may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Choi, S., Victorson, D., Yount, S., Anton, S., & Cella, D. Development of a conceptual framework and calibrated item banks to measure patient reported dyspnea severity and related functional limitations. Value in Health 2011; 14: 291-306. Ruo, B., Choi, S., Baker, D., Grady, K., & Cella,D. Development and validation of a computer adaptive test measuring dyspnea in heart failure. Journal of Cardiac Failure 2010; 16(8): 659-668. doi: 10.1016/j.cardfail.2010.03.002. Victorson, D., Anton, S., Hamilton, A., Yount, S., & Cella, D. A conceptual model of the experience of dyspnea and functional limitations in COPD. Value in Health 2009; 12(6): 1018-1025. Yount, S., Choi, S., Victorson, D., Ruo, B., Ray, D., Cella, D., Anton, S., & Hamilton, A. (2011) Brief, valid measures of dyspnea and related functional limitations in chronic obstructive pulmonary disease (COPD). Value in Health 2011; 14: 307-315. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-Dyspnea Functional Assessment of Chronic Illness Therapy - Dyspnea-10 item LEARN MORE PROMIS SF v1.0 – Dyspnea Severity 10a Patient-Reported Outcomes Measurement Information System Short Form - Dyspnea Severity 10a LEARN MORE PROMIS SF v1.0 – Dyspnea Severity 5a Patient-Reported Outcomes Measurement Information System Short Form - Dyspnea Severity 5a LEARN MORE

Download scoring documents for this measure. BACK MICRA Scoring Downloads Download DOC

peds FAACT-10 Pediatric Functional Assessment of Anorexia/Cachexia Treatment – 10 item version Pediatric Functional Assessment of Anorexia/Cachexia Treatment – 10 item version LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the peds FAACT measure: MEASURE NAME: Pediatric Functional Assessment of Anorexia/Cachexia Treatment – 10 item version VERSION: 2 NUMBER OF ITEMS: 10 PATIENT POPULATION: Pediatric cancer patients 8-18 years old RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Not available TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. RELATED MEASURES: peds FACT-Br , peds FACIT-F , peds FAACT DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the peds FAACT-10 can be obtained by registering for permission. Users are not permitted to translate the peds FAACT-10 without permission from FACIT.org. Permission from FACIT.org to translate the peds FAACT-10 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures peds FACT-Br Pediatric Functional Assessment of Chronic Illness Therapy – Brain LEARN MORE peds FACIT-F Pediatric Functional Assessment of Chronic Illness Therapy – Fatigue LEARN MORE peds FAACT Pediatric Functional Assessment of Anorexia/Cachexia Treatment LEARN MORE

FACT-PSI Functional Assessment of Cancer Therapy - Pulmonary Symptom Index For patients with Lung cancer; a Pulmonary Symptom Index LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FACT-PSI is a 4 item subset of the FACT-LCS which measures pulmonary symptoms in patients with lung cancer. The Functional Assessment of Cancer Therapy-Lung (FACT-L) Scale is a 36-item self-report instrument that measures multidimensional quality of life. It was developed from 1987-1993 and first published in 1995. The FACT-L meets a growing need for disease-specific health-related quality of life (HRQOL) questionnaires that address the general and unique concerns of patients diagnosed with lung cancer. Subsequent to its development, its results have been published in over 25 papers from over 15 unique data sets including over 4,000 people with lung cancer. Since 1995, studied groups have included cancer patients receiving chemotherapy, cancer patients receiving radiotherapy, terminally-ill patients and disease-free survivors. It is a widely-used, reliable and valid measure of multidimensional health status among people with lung cancer. It is brief, has clearly-written, easy-to-read questions, flexible modes of administration shown to be equivalent, and is translated in several dozen languages. MEASURE NAME: Functional Assessment of Cancer Therapy - Pulmonary Symptom Index (FACT-PSI) VERSION: 4 NUMBER OF ITEMS: 4 PATIENT POPULATION: Lung cancer patients 18 and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Pulmonary Symptom Index TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. RELATED MEASURES: FACT-L , FLSI , NFLSI-17 , FLSI-12 , FACT-LCS DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-PSI can be obtained by registering for permission. Users are not permitted to translate the FACT-PSI without permission from FACIT.org. Permission from FACIT.org to translate the FACT-PSI may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Rosenberg, T., Möller, S., Abildgaard, N., Nørgaard, J.N., Lysén, A., Tsykonova, G., Joao, C., Vangsted, A., Schjesvold, F. and Nielsen, L.K. (2024), Health-Related Quality of Life During Carfilzomib–Lenalidomide–Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study. Eur J Haematol. https://doi.org/10.1111/ejh.14358 . Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-L Functional Assessment of Cancer Therapy – Lung LEARN MORE FLSI Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 6 Item Version LEARN MORE NFLSI-17 Functional Assessment of Cancer Therapy Lung Cancer Symptom Index – 17 Item Version LEARN MORE

Download scoring documents for this measure. BACK CRRS Scoring Downloads Download PDF

FACIT-Sp Non-Illness Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being - Non-Illness Version Non-Illness Version of the 12-item Spiritual Well-Being Scale LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FACIT-Sp Non-Illness Version is identical to the FACIT-Sp-12 aside from minor modifications to two items in which “illness” has been revised to “difficult times.” MEASURE NAME: Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being (FACIT-Sp) Non-Illness Version VERSION: 4 NUMBER OF ITEMS: 12 PATIENT POPULATION: Subjects 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Spiritual Well-Being, Meaning, Peace, Faith TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACIT-Sp , FACIT-Sp-Ex , FACIT-SP-12 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACIT-Sp Non-Illness Version can be obtained by registering for permission. Users are not permitted to translate the FACIT-Sp Non-Illness Version without permission from FACIT.org. Permission from FACIT.org to translate the FACIT-Sp Non-Illness may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bormann, J., Aschbacher, K., Wetherell, J., Roesch, S., & Redwine., L. Effects of faith/assurance on cortisol levels are enhanced by a spiritual mantram intervention in adults with HIV: A randomized trial. Journal of Psychosomatic Research 2009; 66: 161–171. doi: 10.1016/j.jpsychores.2008.09.017. Bormann, J., Gifford, A., Shively, M., Smith, T., Redwine, L., Kelly, A., Becker, S., Gershwin, M., Bone, P., & Belding, W. Effects of Spiritual Mantram Repetition on HIV Outcomes: A Randomized Controlled Trial. Journal of Behavioral Medicine 2006; 29(4): 359-376. doi: 10.1007/s10865-006-9063-6. Brady, M.J., Peterman, A.H., Fitchett, G., Mo, M., & Cella, D. A case for including spirituality in quality of life measurement in oncology. Psycho-Oncology 1999; 8: 417-428. Bredle, J., Salsman, J., Debb, S., Arnold, B., & Cella, D. Spiritual Well-Being as a component of health-related quality of life: the functional assessment of chronic illness therapy—spiritual well-being scale (FACIT-Sp). Religions 2011; 2(1): 77-94. doi: 10.3390/rel2010077. Canada, A, Murphy, P., Fitchett, G., Peterman, A., & Schover, L. A 3-factor model for the FACIT-Sp. Psycho-Oncology 2008; 17: 908–916. doi: 10.1002/pon.1307.   Cotton, S., Levine, E., Fitzpatrick, C., Dold, K, & Targ, E. Exploring the relationships among spiritual well-being, quality of life, and psychological adjustment in women with breast cancer. Psycho-Oncology 1999; 8: 429–438. Dapueto, J., Servente, L., Francolino, C., & Hahn, E. Determinants of Quality of Life in Patients with Cancer: A South American Study. Cancer 2005; 103(5): 1072-1081. doi: 10.1002/cncr.20870. Edmondson, D., Park, C., Blank, T., Fenster, J., & Mills, M. Deconstructing spiritual well-being: existential well-being and HRQOL in cancer survivors. Psycho-Oncology 2008; 17: 161–169. doi: 10.1002/pon.1197. Fradelos, E., Tzavella, F., Koukia, E., Tsaras, K., Papathanasiou, I., Aroni, A., Alikari, V., Ralli, M., Bredle, J., & Zyga1, S. The translation, validation and cultural adaptation of functional assessment of chronic illness therapy – spiritual well-being 12 (FACIT-SP12) scale in Greek language. Mater Sociomed 2016; 28(3): 229-234. doi: 10.5455/msm.2016.28.229-234. Jarafi, N., Zamani, A., Lazenby, M., Farajzadegan, Z., Emami, H., & Loghmani, A. Translation and validation of the Persian version of the functional assessment of chronic illness therapy—Spiritual well-being scale (FACIT-Sp) among Muslim Iranians in treatment for cancer. Palliative and Supportive Care 2013; 11: 29–35. doi:10.1017/S1478951512000727. Krupski, T., Kwan, L., Fink, A., Sonn, G., Maliski, S., & Litwin, M. Spirituality Influences Health Related Quality of Life in Men with Prostate Cancer. Psycho-Oncology 2006; 15: 121–131. doi: 10.1002/pon.929. Lazenby, M., Khatib, J., 2, Al-Khair, F., & Neamat, M. Psychometric properties of the Functional Assessment of Chronic Illness Therapy—Spiritual Well-being (FACIT-Sp) in an Arabic-speaking, predominantly Muslim population. Psycho-Oncology 2011; 22(1): 220-227. doi: 10.1002/pon.2062. McClain, C., Rosenfeld, B., & Breitbart, W. Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients. The Lancet 2003; 361: 1603-1607. McClain-Jacobson, C., Rosenfeld, B., Rosenfeld, B., Kosinski, A., Pessin, H., Cimino, J., & Breitbart, W. Belief in an afterlife, spiritual well-being and end-of-life despair in patients with advanced cancer. General Hospital Psychiatry 2004; 26: 484-486. doi: 10.1016/j.genhosppsych. Morgan, P., Gaston-Johansson, F., & Mock, V. Spiritual Well-Being, Religious Coping, and the Quality of Life of African American Breast Cancer Treatment: A Pilot Study. The ABNF Journal 2006; 73-77. Murphy, P., Canada, A., Fitchett, G., Stein, K., Portier, K., Crammer, C., & Peterman, A. An examination of the 3-factor model and structural invariance across racial/ethnic groups for the FACIT-Sp: a report from the American Cancer Society’s Study of Cancer Survivors-II (SCS-II). Psycho-Oncology 2010; 19: 264–272. doi: 10.1002/pon.1559. Perkins, E., Small, B., Balducci, L., Extermann, M., Robb, C., & Haley, W. Individual differences in well-being in older breast cancer survivors. Critical Reviews in Oncology/Hematology 2007; 62: 74-83. doi: 10.1016/j.critrevonc.2006.11.002. Peterman, A., Fitchett, G., Brady, M., & Hernandez, L. Measuring Spiritual Well-Being in People With Cancer: The Functional Assessment of Chronic Illness Therapy—Spiritual Well-Being Scale (FACIT-Sp). Annals of Behavioral Medicine 2002; 24(1):49–58. Rodin, G., Zimmermann, C., Rydall, A., Jones, J., Shepherd, A., Moore, M., Fruh, M., Donner, A., Gagliese, L. The Desire for Hastened Death in Patients with Metastatic Cancer. Journal of Pain and Symptom Management 2007; 33(6): 661-674. doi: 10.1016/j.jpainsymman. Rodin, G., Lo, C., Mikulincer, M., Donner, A., Gagliese, L., & Zimmermann, C. Pathways to distress: The multiple determinants of depression, hopelessness, and the desire for hasted death in metastatic cancer patients. Social Science & Medicine 2008; 68: 562–569. doi: 10.1016/j.socscimed. Schnoll, R., Harlow, L., & Brower, L. Spirituality, Demographic, and Disease Factors, and Adjustment to Cancer. Cancer Practice 2000; 8(6): 298-304. Stefanek, M., McDonald, P., & Hess, S. Religion, Spirituality and Cancer: Current Status and Methodological Challenges. Psycho-Oncology 2005; 14: 450–463. doi: 10.1002/pon.861. Stojković, S. & Prlić, N. Effect of faith on the acceptance of chronic disease patients. South Eastern Europe Health Sciences Journal 2012; 2(1): 52-61. Tate, D. & Forchheimer, M. Quality of Life, Life Satisfaction, and Spirituality: Comparing Outcomes Between Rehabilitation and Cancer Patients. American Journal of Physical Medicine & Rehabilitation 2002; 81(6): 400-410. Trevino, K., Pargament, K., Cotton, S., Leonard. A., Hahn, J., Caprini-Faigin, C., & Tsevat, J. Religious Coping and Physiological, Psychological, Social, and Spiritual Outcomes in Patients with HIV/AIDS: Cross-sectional and Longitudinal Findings. AIDS and Behavior 2010; 14: 379-389. doi: 10.1007/s10461-007-9332-6. Visser, A., Garssen, B., & Vingerhoets, A. Spirituality and well-being in cancer patients: a review. Psycho-Oncology 2010; 19: 565–572. doi: 10.1002/pon. Zavala, M., Maliski, S., Kwan, L., Fink, A., & Litwin, M. Spirituality and quality of life in low-income men with metastatic prostate cancer. Psycho-Oncology 2009; 18: 753–761. doi: 10.1002/pon.1460. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-Sp Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being LEARN MORE FACIT-Sp-Ex Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being Expanded Version LEARN MORE FACIT-Sp-12 Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale LEARN MORE

Download scoring documents for this measure. BACK FACT-NP Scoring Downloads Download DOC

Download scoring documents for this measure. BACK FPSI Scoring Downloads Download DOC